Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

This study has been completed.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: May 24, 2002
Last updated: April 1, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)